Nilotinib nanoparticle formulation - Xspray Pharma

Drug Profile

Nilotinib nanoparticle formulation - Xspray Pharma

Alternative Names: HyNap-Nilo; RightSize nilotinib; XS 003

Latest Information Update: 26 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Xspray Pharma
  • Class Antineoplastics; Benzamides; Imidazoles; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 26 Mar 2018 Chemical structure information added
  • 13 Feb 2018 Clinical development is ongoing (Xspray Pharma pipeline, February 2018)
  • 12 Feb 2018 Xspray Pharma has patent protection for HyNap technology in USA, Canada, Europe, Japan and China (Xspray Pharma website, February 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top